Reasons for selection of GBM are as follows: (i) sytemic application of NDV to GBM patients has resulted, in single-case studies, to impressive results [147,148], (ii) apparently, NDV could pass the blood-brain barrier after systemic application [148], (iii) Rac1 targeting by NDV at the invasion front of migratory GBM cells [93,104]. This evidence concerns the gene RAC1 and glioblastoma.